News circulated recently that the DEA had rescheduled cannabidiol (CBD), the nonpsychoactive ingredient in cannabis, but the technicalities of the agency’s decision actually show their ruling is highly restrictive.
The decision concerned a recently FDA-approved pharmaceutical version of CBD, produced by GW Pharmaceuticals. Due to the federal government’s continued prohibition of cannabis Epidiolex was prohibited from going to market unless the DEA rescheduled CBD. That’s what the agency did, leading some to believe that “since this FDA-approved medication is pure cannabidiol (CBD) that all CBD products fall into the same category,” Forbes noted.
But that is not the case. The DEA decision applies only to “FDA-approved” drugs, meaning they have just granted GW Pharmaceuticals a monopoly on plant-derived CBD (hemp-derived CBD is no longer restricted). The DEA said as much in a statement to NBC affiliate WTHR:
“What this does not do is legalize or change the status of CBD oil products,” DEA spokesperson Rusty Payne said. “As of right now, any other CBD product other than Epidiolex remains a Schedule I controlled substance, so it’s still illegal under federal law.”
“The rescheduling move does open the door for additional high-CBD medicines to enter the US market, however, and it will likely attract other CBD drugmakers to jump in. But many popular products in existing medical cannabis markets, such as Canada or certain US states, will be ineligible due to the amount of THC they contain.”
The decision does make some research into CBD less restricted, but for now, it will only apply to studies conducted on Epidiolex. Ryan Vandrey, an associate professor at Johns Hopkins University Department of Psychiatry and Behavioral Sciences who studies the pharmacology of cannabis, explained the implications. As reported by the university’s news service, The Hub:
“With the DEA’s decision, the door is at least ajar for more sophisticated research, but Vandrey notes that it would take a broader reclassification of CBD overall to see clinical trials using anything beyond Epidiolex.”
For now, research is otherwise still limited:
“For example, Vandrey is currently conducting a study using a pure synthetic CBD formulation that remains a Schedule I substance and requires extra DEA regulation and oversight. Such constraints, he says, slow down the development of new drugs containing not only CBD but all other marijuana compounds.”
Nevertheless, Johns Hopkins Bloomberg School of Public Health researcher Caleb Alexander, who headed the FDA advisory committee that suggested the agency approve Epidiolex, believes times are changing. “I think this will stimulate further investigation into the potential medicinal value of different components of the marijuana plant,” he said. “We’re not talking about one or two chemicals here—there are dozens.“